Journal of South Asian Federation of Obstetrics and Gynaecology

Register      Login

VOLUME 10 , ISSUE 1 ( January-March, 2018 ) > List of Articles

ORIGINAL ARTICLE

Mifepristone in Fibroids: An Alternative!

Sunita Lamba, Aabha Singh

Keywords : Fibroid volume, Leiomyoma, Mean uterine size, Medical management, Mifepristone, Symptomatic fibroids

Citation Information : Lamba S, Singh A. Mifepristone in Fibroids: An Alternative!. J South Asian Feder Obs Gynae 2018; 10 (1):29-32.

DOI: 10.5005/jp-journals-10006-1553

Published Online: 01-12-2018

Copyright Statement:  Copyright © 2018; The Author(s).


Abstract

Introduction: Medical management is a keystone in managing symptomatic fibroids. Availability of an effective, safe, and costeffective medical treatment should always be considered as an alternative to reduce the cost, morbidity, and impact of avoidable major surgeries. Objective: To study the effect of 10 mg Mifepristone on symptomatic fibroids. Materials and methods: This prospective study was conducted at a tertiary care center in Raipur. Fifty women of the reproductive age group with symptomatic uterine fibroids with normal liver and kidney function tests were recruited. A total of 10 mg of oral Mifepristone was administered daily for 3 months. Monthly symptomatic assessment, ultrasonography, and biochemical parameters were done to assess changes. Results: There was significant reduction in menstrual blood loss (MBL) and associated symptoms. Amenorrhea occurred in 100% of women after 3 months of treatment. The fibroid volume and mean uterine size reduced by 26.2 and 26.99% respectively. Mean hemoglobin levels increased by 1.93 gm/dL. Observed side effects were few and tolerable. Conclusion: Mifepristone is an effective and safe alternative for the management of leiomyoma.


PDF Share
  1. Bagaria M, Suneja A, Vaid NB, Guleria K, Mishra K. Low dose Mifepristone in treatment of uterine leiomyomas: a randomized double blind placebo controlled clinical trial. Aust NZ J Obstet Gynecol 2009 Feb;49(1):77-83.
  2. Cabonell Esteve JL, Ascota R, Heredia B, Perez Y, Castaneda MC, Hernendez AV. Mifepristone for the treatment of uterine leiomyomas: a randomized controlled trial. Obstet Gynecol 2008 Nov;112(5):1029-1036.
  3. Feng C, Meldrum S, Fiscella K. Improved quality of life is partly explained by fewer symptoms after treatment of fibroids with Mifepristone. Int J Gynaecol Obstet 2010 May;109(2):121-124.
  4. Engman M, Granberg S, Williams AR, Meng CX, Lalitkumar PG, Gemzell-Danielsson K. Mifepristore for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Hum Reprod 2009 Aug;24(8):1870-1879.
  5. Eisinger SH, Fiscella J, Bonfiglio T, Meldrum S, Fiscella K. Open-label study of ultra low-dose Mifepristone for the treatment of uterine leiomyomata. Eur J Obstet Gynecol 2009 Oct;146(2):215-218.
  6. Mukherjee S, Chakraborty SA. Study evaluating the effect of mifepristone (RU-486) for the treatment of leiomyomata uteri. Niger Med J 2011 Jul;52(3):150-152.
  7. Shikha S, Neeru G, Ekta S, Mathur AS, Garima G. Effect of mifepristone (25 mg) in treatment of uterine myoma in perimenopausal woman. J Midlife Health 2013 Jan-Mar;4(1):22-26.
  8. Kulshrestha V, Kriplani A, Agarwal N, Sareen N, Garg P, Hari S, Thulkar J. Low dose mifepristone in medical management of uterine leiomyoma—an experience from a tertiary care hospital from north India. Indian J Med Res 2013 Jun; 137(6):1154-1162.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.